Add Company
Join Now

NexImmune Revenue and Competitors

License our Company Data API

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • NexImmune's estimated annual revenue is currently $8.5M per year.(i)
  • NexImmune's estimated revenue per employee is $155,000

Employee Data

  • NexImmune has 55 Employees.(i)
  • NexImmune grew their employee count by -39% last year.

NexImmune's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
CSO - Head Preclinical Immunotherapy and Platform DevelopmentReveal Email/Phone
3
CFOReveal Email/Phone
4
VP, ControllerReveal Email/Phone
5
Head Business DevelopmentReveal Email/Phone
6
SVP Preclinical Immunotheraphy and Head Cell BiologyReveal Email/Phone
7
EVP, R&DReveal Email/Phone
8
SVP, Corporate AffairsReveal Email/Phone
9
VP, Corporate ControllerReveal Email/Phone
10
SVP, Translational ScienceReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.3M20%N/AN/A
#2
$3.6M46-31%$17.5MN/A
#3
$3.6M46-34%$10.5MN/A
#4
$30.2M1560%$69.4MN/A
#5
$11.8M76-15%N/AN/A
#6
$1.7M110%N/AN/A
#7
$2.5M160%N/AN/A
#8
$8.8M5719%N/AN/A
#9
$0.2M1-86%N/AN/A
#10
$2M1318%N/AN/A
Add Company

What Is NexImmune?

NexImmune is an emerging biopharmaceutical company advancing a new generation of immunotherapies based on our proprietary AIMâ„¢ technology. This nanotechnology platform, originally developed at Johns Hopkins University, is the foundation for an innovative approach to immunotherapy in which the body's own immune system is stimulated to orchestrate a targeted T cell response against a disease. Central to the AIM technology are artificial Antigen Presenting Cells (aAPC) that present antigens to T cells eliciting a highly targeted therapy driven by the patient's immune system. These aAPC can be rapidly engineered to elicit a specific immune attack that can be directed toward any foreign substance or cell type in a patient's body.

keywords:N/A

N/A

Total Funding

55

Number of Employees

$8.5M

Revenue (est)

-39%

Employee Growth %

N/A

Valuation

N/A

Accelerator

NexImmune News

2022-04-20 - Should You Sell Neximmune Inc (NEXI) Stock Thursday?

Neximmune Inc (NEXI) stock is down -89.56% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy.

2022-04-17 - NexImmune Announces Preclinical Research Collaboration ...

NexImmune is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body's own T cells to...

2022-04-06 - NexImmune Promotes Mathias Oelke, Ph.D., To Chief ...

NexImmune is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body's own T cells to...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$14.4M556%N/A
#2
$13.4M552%N/A
#3
$14.4M552%N/A
#4
$12M56-2%N/A
#5
$16.8M5712%N/A